On 15 October 2025, Omeros Corporation announced a definitive asset purchase and license agreement with Novo Nordisk that grants Novo exclusive global rights to develop and commercialize Omeros’ MASP‑3 inhibitor zaltenibart (OMS906) for rare blood and kidney disorders. The transaction provides Omeros with an upfront payment of $340 million and the potential to receive up to $2.1 billion in milestone payments and tiered royalties, a substantial infusion of capital that directly addresses the company’s liquidity constraints and supports the commercialization of its lead asset, narsoplimab.
The deal is expected to close in the fourth quarter of 2025 and includes provisions that allow Omeros to retain certain rights to its pre‑clinical MASP‑3 programs unrelated to zaltenibart. By transferring the commercial development rights to Novo, Omeros gains immediate cash and a strategic partner with global reach, while Novo gains a novel complement‑targeted therapy that could fill unmet needs in paroxysmal nocturnal hemoglobinuria and other rare disorders.
This transaction represents the largest financing event announced by Omeros in the past year, providing a critical capital buffer that mitigates the company’s ongoing liquidity challenges and positions it to advance its pipeline and potentially secure regulatory approval for narsoplimab.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.